Skip to main navigation

Investor Relations

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials
- SEC Filings
- Quarterly Results
Governance
IR Resources

Press Releases

Year

Dec 12, 2024

Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01

Dec 03, 2024

Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation

Oct 08, 2024

Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01

Oct 01, 2024

Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial

Sep 19, 2024

Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Sep 19, 2024

Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation

Aug 14, 2024

Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation

Aug 09, 2024

Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial

Aug 01, 2024

Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01

Jul 18, 2024

Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22

Investor Tools

Print

RSS Feeds

Email Alerts

Investor Contact

Copyright © 2024 Kiromic BioPharma, Inc. All rights reserved.